A 70-year-old man presented to Tufts emergency department with a 2-day history of left eye redness and periorbital swelling ...

Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...

Novel approach designed to address dysregulated RNA splicing events that drive tumor growth and disease progression across ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Game two of the World Series, played Saturday night in Toronto, will include a performance by the Jonas Brothers in tribute ...

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...

Q1 2026 Earnings Call November 5, 2025 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced an ...

According to reporting from Reuters, reviewers at the agency pointed to an inability to differentiate from placebo to justify rejecting the drug, but an FDA office director approved the drug anyway.

Working with the same tumor slices that pathologists use to diagnose and guide treatment of patients, however, Carstens can ...

Long-lasting fatigue, unexplained fevers, strange bruising, or swollen lymph nodes are signals that should not be ignored, as ...

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of ...